Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Aug 14;32(8):429–433. doi: 10.1002/clc.20583

Prophylaxis to Prevent Infective Endocarditis: To Use or Not to Use?

Abhijeet Dhoble 1,✉, Ameeth Vedre 1,2, Sahar S Abdelmoneim 3,4, Srikar Reddy Sudini 2, Amit Ghose 5, George S Abela 1,2, Milind Karve 6
PMCID: PMC6653586  PMID: 19685514

Abstract

The American Heart Association (AHA) published their revised guidelines in 2007 in which they markedly limited the recommendations for the use of antimicrobial prophylaxis for the prevention of infective endocarditis (IE), except for patients who are at highest risk of adverse outcomes. A recent focused update on valvular heart diseases changed the recommendation for antibiotic use for patients with many underlying heart conditions including mitral valve prolapse (MVP) which were considered as “low risk” heart defects. In this article, we argue that antibiotic prophylaxis should be considered until concrete clinical evidence is provided to dispute against the use of this strategy, especially for patients with MVP. This approach is cost efficient, and provides a chance to prevent a dreadful disease. We have also enlisted 2 clinical cases to support our argument. These are not uncommon clinical scenarios, and emphasize that IE can be fatal in spite of optimum treatment. Patients have the right to make the final decision, and they should be allowed to participate in choosing for or against this approach until adequate clinical evidence is available. Copyright © 2009 Wiley Periodicals, Inc.

Full Text

The Full Text of this article is available as a PDF (185.9 KB).

References

  • 1. Nishimura RA, Carabello BA, Faxon DP, et al. ACC/AHA 2008 Guideline update on valvular heart disease: focused update on infective endocarditis: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2008; 52(8): 676–685. [DOI] [PubMed] [Google Scholar]
  • 2. Wilson W, Taubert KA, Gewitz M, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Surgery and Anesthesia; Quality of Care and Outcomes Research Interdisciplinary Working Group. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007; 116(15): 1736–1754. [DOI] [PubMed] [Google Scholar]
  • 3. Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacterial endocarditis: recommendations by the American Heart Association. JAMA 1997; 277: 1794–1801. [PubMed] [Google Scholar]
  • 4. Horstkotte D, Follath F, Gutschik E, et al; Task Force Members on Infective Endocarditis of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG); Document Reviewers. Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary; the task force on infective endocarditis of the European Society of Cardiology. Eur Heart J 2004; 25(3): 267–276. [DOI] [PubMed] [Google Scholar]
  • 5. Gould FK, Elliott TS, Foweraker J, et al; Working Party of the British Society for Antimicrobial Chemotherapy. Guidelines for the prevention of endocarditis: report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2006; 57(6): 1035–1042. [DOI] [PubMed] [Google Scholar]
  • 6. Richey R, Wray D, Stokes T; Guideline Development Group. Prophylaxis against infective endocarditis: summary of NICE guidance. BMJ 2008; 336(7647): 770–771. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Jones TD, Baumgartner L, Bellows MT, et al; Committee on Prevention of Rheumatic Fever and Bacterial Endocarditis, American Heart Association. Prevention of rheumatic fever and bacterial endocarditis through control of streptococcal infections. Circulation 1955; 11: 317–320. [Google Scholar]
  • 8. Millar BC, Moore JE. Emerging issues in infective endocarditis. Emerg Infect Dis 2004; 10(6): 1110–1116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Weaver WD, Nishimura RA, Warnes CA. President's page: antimicrobial prophylaxis to prevent infective endocarditis: why did the recommendations change? J Am Coll Cardiol 2008; 52(6): 495–497. [DOI] [PubMed] [Google Scholar]
  • 10. Roberts GJ. Dentists are innocent! “Everyday” bacteremia is the real culprit: a review and assessment of the evidence that dental surgical procedures are a principal cause of bacterial endocarditis in children. Pediatr Cardiol 1999; 20: 317–325. [DOI] [PubMed] [Google Scholar]
  • 11. Oliver R, Roberts GJ, Hooper L. Penicillins for the prophylaxis of bacterial endocarditis in: Dentistry. Cochrane Database Syst Rev 2004; CD003813 http://mrw.interscience.wiley.com/cochrane/ clsysrev/articles/CD003813/frame.html. Accessed January 1, 2009. [DOI] [PubMed] [Google Scholar]
  • 12. Grau JB, Pirelli L, Yu PJ, Galloway AC, Ostrer H. The genetics of mitral valve prolapse. Clin Genet 2007; 72(4): 288–295. [DOI] [PubMed] [Google Scholar]
  • 13.Epocrates Online Formulary. Amoxicillin manufacturing pricing. Available at https://online.epocrates.com/noFrame/show‐ Page. do?method = drugs&MonographId = 139. Accessed August 31, 2008.
  • 14. Pham P, Bartlett JG. John Hopkins Antibiotic Guide: Natural Penicillin. 03‐12‐2008. Available at http://prod.hopkinsabxguide.org/ antibiotics/antibacterial/natural_pcns/penicillin.html?contentIns‐ tanceId = 25488. Accessed August 31, 2008.
  • 15. MacMahon SW, Hickey AJ, Wilcken DE, Wittes JT, Feneley MP, Hickie JB. Risk of infective endocarditis in mitral valve prolapse with and without precordial systolic murmurs. Am J Cardiol 1987; 59(1): 105–108. [DOI] [PubMed] [Google Scholar]
  • 16. Rossi EG, Grinberg M, Mansur AJ, Bellotti G, Pileggi F, Jatene A. Mitral valve prolapse in infective endocarditis. Incidence and characteristics. Arq Bras Cardiol 1990; 54(2): 101–104. [PubMed] [Google Scholar]
  • 17. Frary CJ, Devereux RB, Kramer‐Fox R, Roberts RB, Ruchlin HS. Clinical and health care cost consequences of infective endocarditis in mitral valve prolapse. Am J Cardiol 1994; 73(4): 263–267. [DOI] [PubMed] [Google Scholar]
  • 18. Devereux RB, Frary CJ, Kramer‐Fox R, Roberts RB, Ruchlin HS. Cost‐effectiveness of infective endocarditis prophylaxis for mitral valve prolapse with or without a mitral regurgitant murmur. Am J Cardiol 1994; 74(10): 1024–1029. [DOI] [PubMed] [Google Scholar]
  • 19. Daly CG, Currie BJ, Jeyasingham MS et al A change of heart: the new infective endocarditis prophylaxis guidelines. Australian Dental Journal 2008. Oct; 53(3): 196–200. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES